• 1. An automated in-chip-catalytic–spectrophotometric method for determination of copper(ii) using a multisyringe flow injection analysis-multipumping flow system?
  Camelia Henríquez,Edwin Palacio,Víctor Cerdà Anal. Methods, 2014,6, 8494-8504
• 2. An antioxidative galactomannan extracted from Chinese Sesbania cannabina enhances immune activation of macrophage cells?
  Chongyang Zhu,Xiaojia Bian,Xin Jia,Ning Tang,Yongqiang Cheng Food Funct., 2020,11, 10635-10644
• 3. Acenaphthenic hopanoids, a novel series of aromatised
  Teresita Carrillo-Hernández,Philippe Schaeffer,Pierre Albrecht Chem. Commun., 2001, 1976-1977
• 4. An approach to C–N activation: coupling of arenesulfonyl hydrazides and arenesulfonyl chlorides with tert-amines via a metal-, oxidant- and halogen-free anodic oxidation??
  M. Sheykhan,S. Khani,S. Shaabanzadeh,M. Joafshan Green Chem., 2017,19, 5940-5948
• 5. An autoreduction method to prepare plasmonic gold-embedded polypeptide micelles for synergistic chemo-photothermal therapy?
  Xingjie Wu,Linzhu Zhou,Yue Su,Chang-Ming Dong J. Mater. Chem. B, 2016,4, 2142-2152

• Solvents and Organic Chemicals Organic Compounds Lipids and lipid-like molecules Steroids and steroid derivatives Gluco/mineralocorticoids, progestogins and derivatives
• Solvents and Organic Chemicals Organic Compounds Lipids and lipid-like molecules Steroids and steroid derivatives Pregnane steroids Gluco/mineralocorticoids, progestogins and derivatives

Professional Introduction to Anecortave (CAS No. 7753-60-8)

Anecortave, with the chemical name 7-[2-hydroxy-3-(3,5-dimethoxyphenyl)propyl]-1H-indazole-3-carboxylic acid, is a compound of significant interest in the field of pharmaceutical chemistry. Its molecular structure and pharmacological properties have positioned it as a promising candidate for various therapeutic applications. This introduction delves into the compound's chemical characteristics, its potential biological activities, and recent advancements in research that highlight its significance.

The chemical formula of Anecortave is C??H??NO?, and it is classified as an indazole derivative. Indazole compounds are known for their diverse biological activities, including anti-inflammatory, antioxidant, and antimicrobial properties. The presence of hydroxyl and methoxy groups in the structure of Anecortave contributes to its unique pharmacophore, enabling interactions with multiple biological targets. These structural features have been extensively studied to understand their role in modulating cellular processes.

Recent studies have focused on the pharmacokinetic profile of Anecortave. Research indicates that the compound exhibits moderate solubility in water and lipids, which is crucial for its absorption and distribution within the body. The half-life of Anecortave in vivo has been reported to be approximately 6 hours, suggesting a reasonable duration of action for therapeutic purposes. These findings are essential for formulating dosage regimens that maximize efficacy while minimizing potential side effects.

Beyond its pharmacokinetic properties, Anecortave has shown promise in preclinical studies for its potential role in treating neurological disorders. Specifically, research has explored its effects on neuroinflammation and oxidative stress, two key pathological mechanisms involved in conditions such as Alzheimer's disease and Parkinson's disease. Studies using cell culture models have demonstrated that Anecortave can inhibit the activation of microglial cells, which are known to contribute to neuroinflammatory responses.

The antioxidant properties of Anecortave have also been a subject of interest. Oxidative stress is a hallmark of many chronic diseases, and compounds that can mitigate this stress are highly sought after. In vitro experiments have shown that Anecortave can scavenge reactive oxygen species (ROS) and protect against oxidative damage in neuronal cells. This protective effect is attributed to its ability to modulate enzymes involved in the antioxidant defense system.

In addition to its neurological applications, Anecortave has been investigated for its potential anti-inflammatory effects. Chronic inflammation is associated with a wide range of diseases, including cardiovascular disorders and autoimmune conditions. Studies have indicated that Anecortave can inhibit the production of pro-inflammatory cytokines such as tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6). By modulating inflammatory pathways, Anecortave may offer therapeutic benefits in managing inflammatory diseases.

The synthesis of Anecortave involves multi-step organic reactions that require precise control over reaction conditions. The indazole core is typically synthesized through cyclization reactions, followed by functional group modifications to introduce the hydroxyl and methoxy groups. Advanced synthetic techniques, such as catalytic hydrogenation and palladium-catalyzed cross-coupling reactions, have been employed to achieve high yields and purity levels. These synthetic methodologies are critical for producing sufficient quantities of Anecortave for both research and potential clinical use.

Quality control measures play a pivotal role in ensuring the consistency and safety of pharmaceutical compounds like Anecortave. Analytical techniques such as high-performance liquid chromatography (HPLC), nuclear magnetic resonance (NMR) spectroscopy, and mass spectrometry (MS) are routinely used to verify the chemical structure and purity of the compound. These analytical methods provide confidence in the compound's integrity throughout the manufacturing process.

The future directions of research on Anecortave include exploring its potential in combination therapies with other drugs. By synergizing multiple therapeutic agents, it may be possible to enhance treatment outcomes while reducing side effects. Additionally, further investigation into the long-term safety profile of Anecortave will be essential before it can be considered for clinical applications. Preclinical toxicology studies are being conducted to assess potential risks associated with chronic use of the compound.

In conclusion,Anecortave (CAS No. 7753-60-8) is a multifaceted compound with significant therapeutic potential across various medical fields. Its unique chemical structure enables interactions with multiple biological targets, making it a versatile candidate for drug development. Recent research highlights its promise in treating neurological disorders, reducing oxidative stress, and modulating inflammatory responses. As ongoing studies continue to uncover new applications for Anecortave, it remains an exciting area of exploration within pharmaceutical chemistry.

• 93239-37-3((6a)-21-(Acetyloxy)-17-hydroxy-6-methylpregna-1,4,9(11)-triene-3,20-dione)
• 28449-20-9(Pregn-4-ene-3,20-dione,21-(acetyloxy)-11,17-dihydroxy-2-methyl-, (2a,11b)- (9CI))
• 426-43-7(Pregn-4-ene-3,20-dione,17,21-dihydroxy-16-methyl-, 21-acetate, (16a)- (9CI))
• 3386-03-6(Pregn-4-ene-3,20-dione,21-(acetyloxy)-17-hydroxy-6-methyl-, (6a)- (9CI))
• 34542-56-8(17,21-Dihydroxy-16alpha-methylpregna-4,9(11)-diene-3,20-dione 21-acetate)
• 10106-41-9(17,21-Dihydroxy-16a-methylpregna-1,4,9(11)-triene-3,20-dione 21-Acetate)
• 53187-58-9(hydrocortisone acetate)
• 96843-92-4(4-pregnene-3,11,20-trione, 17alpha,21-dihydroxy-, 21-acetate)
• 910-99-6(Pregna-1,4,9(11)-triene-3,20-dione,21-(acetyloxy)-17-hydroxy-16-methyl-, (16b)-)
• 60620-33-9([2-[(8S,9S,10R,11S,13S,14S,17R)-11,17-dihydroxy-10,13-dimethyl-3-oxo-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-17-yl]-2-oxo-ethyl] acetate)